GH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Guardant Health Inc (GH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company demonstrates strong revenue growth and improving financial metrics, the technical indicators, options sentiment, and lack of recent positive news or catalysts suggest a neutral stance. Additionally, the stock's recent price trends and lack of proprietary trading signals do not present a compelling entry point.
The MACD is below 0 and negatively contracting, RSI is neutral at 47.622, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 87.002, with key support at 77.662 and resistance at 96.342.
Analysts maintain mostly positive ratings with several buy and overweight ratings. Price targets range from $90 to $150, indicating potential upside. The company has strong revenue growth (39.37% YoY) and improving gross margins.
No recent news or event-driven catalysts. The stock's technical indicators do not show bullish momentum. Options data reflects bearish sentiment, and there is no recent congress trading data to indicate insider confidence.
In Q4 2025, revenue increased by 39.37% YoY to $281.27M. Net income improved by 15.75% YoY but remains negative at -$128.49M. EPS improved by 11.11% YoY to -1, and gross margin increased by 5% to 64.63%.
Analysts are generally positive, with several buy and overweight ratings. Price targets have been adjusted downward recently, but they still suggest significant upside potential. Barclays, Citi, and Wells Fargo highlight potential catalysts and sector strength despite risks.
